Home
About Us
- Company Overview
- Our Team
Science
- Science Overview
- SIGMA platform
Therapeutic Focus
Pipeline
Clinical Trials
Newsroom
Contact Us

Home
About Us
- Company Overview
- Our Team
Science
- Science Overview
- SIGMA platform
Therapeutic Focus
Pipeline
Clinical Trials
Newsroom
Contact Us

Team

Search on the website:

Recent Related Scientific Papers:

Activation of the sigma-1 receptor ameliorates neuronal ferroptosis via IRE1α after spinal cord injury
Cytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk
Deletion of Sigmar1 leads to increased arterial stiffness and altered mitochondrial respiration resulting in vascular dysfunction

Categories:

Alzheimer's Disease
Parkinson's Disease
Epilepsy
Childhood Absence
Fragile X and RETT syndromes
Neuropathic Cancer Pain
Huntington's Disease
ALS
Cardiovascular Diseases
Cancer
Osteoarthritis
Autoimmune Diseases
Mental Disorders
Aging
Metabolic Diseases
Antiviral
Proteostasis
Sigma-1 receptor
Sigma-2 receptor

RSS Feed
LinkedIn

Forward-Looking Statements

This note contains important information about our forward-looking statements

© Copyright 2021-2023 Advantx Pharmaceuticals Inc. All Right Reserved – Privacy